Bulk Pharmaceutical API Sources for QELBREE

Bulk Pharmaceutical API Sources for QELBREE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		71424
AAA Chemistry		AR-1F1479
ABI Chem		AC1L2G58
ABI Chem		AC1Q3DNH

Qelbree API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global landscape of bulk active pharmaceutical ingredient (API) sources for Qelbree (viloxazine), a selective norepinephrine reuptake inhibitor (SNRI) used for treating attention-deficit/hyperactivity disorder (ADHD) in pediatric patients. The analysis focuses on API manufacturers, their capacities, regulatory compliance, and geographical distribution, providing critical intelligence for supply chain management and procurement strategies.

What is the Current State of Qelbree API Manufacturing?

Qelbree's active pharmaceutical ingredient is viloxazine. The manufacturing of viloxazine API involves complex chemical synthesis. Key players in this space are typically specialized chemical manufacturers with expertise in complex organic synthesis and adherence to stringent Good Manufacturing Practices (GMP).

The global API market is dominated by a few key regions, including China, India, Europe, and North America. For viloxazine, specific manufacturers have emerged as significant suppliers. The supply chain for Qelbree API is characterized by a need for high purity and consistent quality to meet pharmaceutical standards.

The current manufacturing landscape is shaped by several factors:

• Regulatory Scrutiny: API manufacturers must comply with FDA, EMA, and other global regulatory body standards. This includes rigorous quality control, documentation, and site inspections.
• Intellectual Property: While Qelbree is an approved drug, the specific synthesis routes for its API may be subject to patents. This can influence the number of authorized manufacturers.
• Cost Pressures: Pharmaceutical companies seek cost-effective API sourcing without compromising quality. This drives competition among manufacturers.
• Supply Chain Resilience: Recent global events have highlighted the importance of diversified and resilient API supply chains, encouraging multiple sourcing options and geographical spread.

Who are the Key Manufacturers of Viloxazine API?

Identifying specific contract manufacturing organizations (CMOs) or proprietary manufacturing sites involved in the large-scale production of viloxazine API is often proprietary information tied to the drug sponsor's supply agreements. However, the general profile of potential suppliers can be characterized:

• Contract Development and Manufacturing Organizations (CDMOs): Companies specializing in pharmaceutical ingredient manufacturing often possess the requisite expertise and infrastructure. These entities typically serve multiple pharmaceutical clients.
• Fine Chemical Manufacturers: Companies with a strong foundation in complex organic synthesis, capable of producing high-purity chemical compounds under GMP conditions.
• In-House Manufacturing: The drug sponsor, Supernus Pharmaceuticals, may operate its own manufacturing facilities for critical APIs or have exclusive agreements with select CDMOs.

Potential Manufacturers and Their Capabilities (General Profile):

Manufacturer Type	Specialization	Regulatory Compliance	Geographical Presence (Typical)
Large-Scale CDMOs	Multi-product API synthesis, process optimization, scale-up	FDA, EMA, PMDA, WHO GMP	Global (India, China, Europe)
Specialized Chemical Synthesizers	Niche complex organic molecules, custom synthesis	FDA, EMA GMP (depending on client agreements)	Europe, North America
Generic API Producers	Cost-efficient high-volume production	FDA, EMA GMP (may vary for less regulated markets)	India, China

Specific company names are not publicly disclosed for Qelbree API production due to confidentiality agreements between Supernus Pharmaceuticals and its suppliers. However, a review of the pharmaceutical API manufacturing landscape indicates that companies with established track records in producing complex small molecules under strict regulatory compliance would be prime candidates. This includes firms with significant GMP-certified facilities and robust quality management systems.

What are the Regulatory Requirements for Viloxazine API Production?

The production of viloxazine API for pharmaceutical use is subject to rigorous regulatory oversight by health authorities worldwide. The primary objective is to ensure the safety, efficacy, and quality of the final drug product. Key regulatory requirements include:

1. Good Manufacturing Practices (GMP): Manufacturers must adhere to cGMP guidelines as defined by the U.S. Food and Drug Administration (FDA) [1], the European Medicines Agency (EMA) [2], and other international regulatory bodies. GMP covers all aspects of production, including personnel, premises, equipment, raw materials, manufacturing processes, quality control, documentation, and distribution.
2. Drug Master File (DMF): API manufacturers typically file a DMF with regulatory agencies like the FDA. The DMF contains confidential, detailed information about the manufacturing, processing, packaging, and storage of the API. This allows the drug sponsor (Supernus Pharmaceuticals) to reference the DMF in their New Drug Application (NDA) or other regulatory submissions without disclosing the manufacturer's proprietary information directly to the sponsor.
3. Quality Control and Assurance: Comprehensive testing is required to confirm the identity, strength, quality, and purity of the viloxazine API. This includes testing for impurities, residual solvents, heavy metals, and microbial contamination. Validated analytical methods are essential.
4. Stability Studies: Manufacturers must conduct stability studies to determine the shelf life of the API under various storage conditions. This data is crucial for setting expiration dates and storage recommendations.
5. Change Control: Any changes to the manufacturing process, raw materials, equipment, or facilities must be carefully managed, documented, and, if necessary, reported to regulatory authorities and the drug sponsor.
6. Site Inspections: Manufacturing facilities are subject to routine inspections by regulatory agencies to ensure ongoing compliance with GMP standards.

Key Regulatory Bodies and Their Standards:

• U.S. Food and Drug Administration (FDA): Enforces current Good Manufacturing Practices (cGMP) through regulations like 21 CFR Parts 210 and 211.
• European Medicines Agency (EMA): Oversees GMP compliance in the European Union, with guidelines published by the EMA and its member states.
• Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Sets stringent GMP standards for Japanese market approval.
• World Health Organization (WHO): Provides international GMP guidelines that are often adopted by national regulatory authorities.

The specific GMP certification and audit history of API manufacturers are critical due diligence factors for Qelbree's supply chain.

What is the Global Capacity for Viloxazine API Production?

Estimating the precise global production capacity for a specific API like viloxazine is challenging as this data is often considered commercially sensitive by manufacturers and drug sponsors. However, an assessment can be made based on the typical production volumes required for a commercially approved drug and the general capacity of established API manufacturers.

Qelbree is approved for the treatment of ADHD in pediatric patients, indicating a significant but not blockbuster-level annual demand. The total annual requirement for viloxazine API would be dictated by:

• Market Penetration: The number of patients prescribed Qelbree.
• Dosage Regimens: The typical daily or weekly dosage per patient.
• Formulation Efficiency: The API yield in the final drug product.

Factors Influencing Capacity Assessment:

• Batch Size: The typical scale of a manufacturing batch (e.g., kilograms to metric tons).
• Campaign Length: The duration a specific production line is dedicated to viloxazine.
• Cycle Time: The time required to complete one batch.
• Number of Manufacturers: The extent of diversification in sourcing.

Assuming a moderate annual demand for Qelbree, the required API capacity would likely be in the range of several metric tons to potentially tens of metric tons annually. This capacity is well within the capabilities of most large-scale CDMOs or specialized fine chemical manufacturers that operate multi-purpose production facilities.

Indicative Capacity Range:

• Low End: 5-10 metric tons per year (sufficient for initial market launch and moderate uptake).
• High End: 20-50 metric tons per year (accommodating significant market growth and stocking).

The existing global infrastructure for small molecule API synthesis, particularly from manufacturers in India and China, coupled with established European and North American players, provides ample capacity to meet Qelbree's projected needs. The primary constraint is not raw capacity but rather the qualification of specific manufacturers by Supernus Pharmaceuticals and their ability to consistently produce API meeting all quality and regulatory specifications.

What are the Potential Supply Chain Risks for Qelbree API?

The global pharmaceutical API supply chain, including that for Qelbree, faces inherent risks that can impact availability, cost, and quality. These risks require strategic mitigation by the drug sponsor and its supply chain partners.

Key Supply Chain Risks:

1. Geopolitical Instability and Trade Restrictions:

   • Impact: Disruptions to international shipping, tariffs, export/import bans, or political unrest in key manufacturing regions (e.g., China, India) can halt or delay API shipments.
   • Example: Sanctions or trade disputes could affect the availability of raw materials or the export of finished API.

2. Regulatory Changes and Enforcement:

   • Impact: New or updated GMP requirements, stricter impurity limits, or increased enforcement actions (e.g., warning letters, import alerts) against API manufacturers can lead to production halts or require costly process changes.
   • Example: A regulatory agency finding non-compliance at a key API site could immediately restrict supply.

3. Raw Material Shortages and Price Volatility:

   • Impact: The synthesis of viloxazine relies on precursor chemicals, some of which may be produced by a limited number of suppliers or are subject to price fluctuations based on market demand and supply dynamics.
   • Example: A shortage of a critical starting material could halt API production for weeks or months.

4. Quality Failures and Recalls:

   • Impact: Batch failures due to manufacturing deviations, contamination, or out-of-specification results can lead to significant delays and the need for batch reprocessing or destruction, impacting inventory. Product recalls due to quality defects can have severe financial and reputational consequences.
   • Example: Discovery of a genotoxic impurity could lead to an immediate recall and a need to revalidate the entire manufacturing process.

5. Manufacturing Capacity Constraints:

   • Impact: While current capacity may be sufficient, unexpected surges in demand or the exit of a key manufacturer from the market could lead to a shortage if alternative suppliers cannot scale up quickly.
   • Example: A competing drug using similar synthetic pathways could increase demand for shared raw materials or manufacturing equipment.

6. Logistical and Transportation Disruptions:

   • Impact: Issues with freight capacity, port congestion, or severe weather events can delay shipments of API from the manufacturing site to the drug product manufacturing facility.
   • Example: Global shipping crises, like those experienced in recent years, can significantly extend lead times.

7. Intellectual Property Disputes:

   • Impact: While the drug itself is approved, disputes over specific manufacturing processes or intermediates could lead to legal challenges and injunctions, impacting production.

Mitigation Strategies:

• Dual/Multi-Sourcing: Qualifying multiple API suppliers in different geographical regions to reduce reliance on a single source.
• Robust Quality Agreements: Establishing clear quality expectations and control measures with suppliers.
• Supply Chain Mapping: Understanding the entire upstream supply chain, including raw material providers.
• Inventory Management: Maintaining appropriate safety stock levels of API and critical raw materials.
• Regular Audits and Performance Monitoring: Continuously assessing supplier performance and compliance.
• Contingency Planning: Developing backup plans for critical raw materials, manufacturing sites, and logistics.

What are the Geographical Considerations for API Sourcing?

The geographical distribution of API manufacturing for Qelbree (viloxazine) plays a critical role in supply chain resilience, cost, and regulatory compliance. Historically, API production has consolidated in regions offering cost advantages and specialized expertise.

Major Sourcing Regions:

1. India:

   • Strengths: Significant manufacturing capacity for a wide range of APIs, established GMP compliance, skilled workforce, cost-effectiveness. India is a major global supplier of generic and branded APIs.
   • Considerations: Increasing regulatory scrutiny from Western agencies, potential for quality variations if not rigorously managed, logistical complexities for outbound shipments.

2. China:

   • Strengths: Extensive manufacturing infrastructure, competitive pricing, large-scale production capabilities for many chemical intermediates and APIs.
   • Considerations: Historically, concerns regarding quality control and intellectual property have existed, though these are improving. Recent geopolitical tensions and stringent environmental regulations can impact production and export.

3. Europe (e.g., Germany, Switzerland, Italy):

   • Strengths: High standards of quality and regulatory compliance (EMA GMP), advanced technological capabilities, strong intellectual property protection, often preferred for complex or high-value APIs.
   • Considerations: Higher manufacturing costs compared to Asian counterparts, potentially longer lead times for raw materials if sourced from outside Europe.

4. North America (e.g., USA, Canada):

   • Strengths: Strict regulatory oversight (FDA GMP), advanced technological capabilities, proximity to end-markets for some products, robust quality systems.
   • Considerations: Typically the highest manufacturing costs, capacity may be more focused on specialized or niche APIs rather than high-volume commodity production.

Strategic Sourcing Implications for Qelbree API:

• Diversification: Relying on manufacturers in multiple regions (e.g., one in India and one in Europe) can mitigate risks associated with single-region disruptions (geopolitical, natural disasters, regulatory crackdowns).
• Quality and Compliance: Prioritizing manufacturers with impeccable regulatory track records (FDA, EMA approved sites) is paramount, regardless of geographical location.
• Cost vs. Risk: Balancing the cost benefits of sourcing from Asia against the potential risks requires careful due diligence and strategic hedging through dual-sourcing.
• Raw Material Origin: Understanding the origin of key starting materials and intermediates is crucial, as their supply chains can also be geographically concentrated and present independent risks.

For Qelbree, a balanced approach, likely involving at least two geographically diverse suppliers with strong GMP credentials, would represent a robust supply chain strategy.

Key Takeaways

• Viloxazine API manufacturing requires specialized capabilities in complex organic synthesis and adherence to stringent GMP standards.
• Key API manufacturers are typically large CDMOs or specialized fine chemical producers with established global footprints, predominantly in India, China, and Europe.
• Regulatory compliance, including FDA and EMA GMP, and the successful filing of Drug Master Files (DMFs), are critical prerequisites for API suppliers.
• Global capacity for viloxazine API is assessed to be sufficient for current and projected market demand, likely in the range of several to tens of metric tons annually.
• Supply chain risks are significant and include geopolitical instability, regulatory changes, raw material volatility, quality failures, and logistical disruptions.
• Geographical diversification of API sourcing, balancing cost with robust quality and regulatory compliance, is essential for supply chain resilience.

Frequently Asked Questions

1. Are there any publicly listed manufacturers of viloxazine API for Qelbree? No, specific API manufacturers for Qelbree are not publicly disclosed due to confidentiality agreements between the drug sponsor, Supernus Pharmaceuticals, and its suppliers.

2. What is the typical purity requirement for pharmaceutical-grade viloxazine API? Pharmaceutical-grade viloxazine API typically requires a purity of 99% or higher, with strict limits on specific impurities, residual solvents, and heavy metals, as defined by pharmacopoeial standards and regulatory filings.

3. Can generic manufacturers produce viloxazine API? Once Qelbree's exclusivity periods expire, generic manufacturers can seek approval to produce viloxazine API, provided they can meet all regulatory and quality requirements and demonstrate bioequivalence.

4. How long does it typically take to qualify a new API manufacturer for a drug like Qelbree? Qualifying a new API manufacturer can take 12 to 24 months, involving site audits, process validation, analytical method validation, stability studies, and regulatory submissions.

5. What is the primary regulatory document that API manufacturers use to provide information to the FDA? API manufacturers typically submit a Drug Master File (DMF) to the FDA, which contains confidential detailed information about the manufacturing process.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA Website (General CPG related to GMP)]

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA Website (General GMP Information)]